Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials

BACKGROUND: Vortioxetine is a novel multimodal compound that has recently been approved by the FDA for the treatment of major depressive disorder (MDD). It is a selective serotonin (5-HT) 3A and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and inhibitor of sero...

Descripción completa

Detalles Bibliográficos
Autores principales: Berhan, Asres, Barker, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189201/
https://www.ncbi.nlm.nih.gov/pubmed/25260373
http://dx.doi.org/10.1186/s12888-014-0276-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189201/
https://www.ncbi.nlm.nih.gov/pubmed/25260373
http://dx.doi.org/10.1186/s12888-014-0276-x

Ejemplares similares